AlgoRx and Corgentech Announce Addition of Ninth Board Member to Proposed Board of Directors for Combined Company
15 11월 2005 - 9:00PM
PR Newswire (US)
SECAUCUS, N.J. and SOUTH SAN FRANCISCO, Calif., Nov. 15
/PRNewswire-FirstCall/ -- AlgoRx Pharmaceuticals, Inc. and
Corgentech Inc. (NASDAQ:CGTK) today announced that Robert L. Zerbe,
M.D. has been proposed as the ninth board member for the combined
company. Dr. Zerbe, who has overseen successful clinical
development programs for products including Lipitor(R) and
Neurontin(R), currently serves as chief executive officer of QuatRx
Pharmaceuticals Company. AlgoRx and Corgentech signed a definitive
agreement to merge in late September, and the stockholder vote is
expected to be completed in mid- December. Pending approval of the
merger, the board of directors of the combined company will be
comprised of Richard B. Brewer, Dr. Charles M. Cohen, Thomas J.
Colligan, Carter H. Eckert, Dr. Rodney A. Ferguson, John P.
McLaughlin, Dr. Arnold L. Oronsky, Dr. Michael F. Powell and Dr.
Robert L. Zerbe. "We expect to have four products in clinical
trials in 2006, the most advanced for which we expect to file a New
Drug Application (NDA) during 2006, so Dr. Zerbe's extensive
background in clinical development and regulatory affairs will be
important in terms of guiding Corgentech through our milestones,"
stated John P. McLaughlin, chief executive officer of Corgentech.
"The proposed board represents an excellent combination of
business, medical and clinical development expertise, and Bob's set
of experiences will be an important complement to the diverse skill
sets of the rest of the board of directors." Robert L. Zerbe, M.D.
founded and has served as the chief executive officer of QuatRx
Pharmaceuticals Company, a biopharmaceutical company, since
December 2000. Dr. Zerbe has extensive experience in regulatory
affairs and global clinical development at Eli Lilly (U.S. &
U.K.), where he held a variety of research and development
positions, including managing director, Lilly Research Center U.K.,
and vice president of clinical investigation and regulatory
affairs. He joined Parke-Davis in 1993, becoming senior vice
president of worldwide clinical research and development, during
which he oversaw the successful clinical development programs for
Lipitor, Neurontin and other key products. Dr. Zerbe earned his
medical degree at Indiana University and did post-graduate training
in internal medicine, endocrinology and neuroendocrinology at
Indiana University and the National Institutes of Mental Health.
About AlgoRx AlgoRx is a private, emerging pharmaceutical company
focused on developing and commercializing a diversified portfolio
of pharmaceutical product candidates to address pain, a large and
under-served market. AlgoRx's portfolio of pain management drug
candidates includes ALGRX 3268, which has completed Phase 3
clinical trials, ALGRX 4975, which is in Phase 2 clinical trials,
and ALGRX 1207, which is soon to enter the clinic. AlgoRx is based
in Secaucus, NJ. For more information on the company and its
technologies, please visit http://www.algorx.com/. About Corgentech
Corgentech is a biopharmaceutical company focused on the
development and commercialization of novel therapeutics for
significant unmet medical needs. Corgentech is based in South San
Francisco, CA. For more information on the company and its
technologies, please visit http://www.corgentech.com/. Forward
Looking Statements This press release includes "forward-looking
statements" within the meaning of the safe harbor provisions of the
United States Private Securities Litigation Reform Act of 1995.
Words such as "expect," "estimate," "project," "budget,"
"forecast," "anticipate," "intend," "plan," "may," "will," "could,"
"should," "believes," "predicts," "potential," "continue," and
similar expressions are intended to identify such forward-looking
statements. Forward- looking statements in this press release
include, without limitation, clinical results forecasts of product
development, FDA filings, benefits of the proposed merger, and
other matters that involve known and unknown risks, uncertainties
and other factors that may cause actual results, levels of
activity, performance or achievements to differ materially from
results expressed or implied by this press release. Such risk
factors include, among others: whether the companies can
successfully develop new products and the degree to which these
gain market acceptance. Actual results may differ materially from
those contained in the forward-looking statements in this press
release. Additional information concerning these and other risk
factors is contained in Corgentech's Form 10-K/A for the year ended
December 31, 2004 and most recently filed Form 10-Q. Corgentech and
AlgoRx undertake no obligation and do not intend to update these
forward-looking statements to reflect events or circumstances
occurring after this press release. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. All forward-looking
statements are qualified in their entirety by this cautionary
statement. Additional Information and Where to Find It Corgentech
Inc. has filed a registration statement on Form S-4/A, and
Corgentech and AlgoRx Pharmaceuticals, Inc. have filed a related
joint proxy statement/prospectus, in connection with the merger
transaction involving Corgentech and AlgoRx. Investors and security
holders are urged to read the registration statement on Form S-4/A
and the related joint proxy statement/prospectus because they
contain important information about the merger transaction.
Investors and security holders may obtain free copies of these
documents and other documents filed with the SEC at the SEC's web
site at http://www.sec.gov/. In addition, investors and security
holders may obtain free copies of the documents filed with the SEC
by contacting Corgentech Investor Relations at the email address: .
Corgentech, AlgoRx and their directors and executive officers may
be deemed to be participants in the solicitation of proxies from
the stockholders of Corgentech and AlgoRx in connection with the
merger transaction. Information regarding the special interests of
these directors and executive officers in the merger transaction is
included in the joint proxy statement/prospectus of AlgoRx and
Corgentech described above. Additional information regarding the
directors and executive officers of Corgentech is also included in
Corgentech's proxy statement for its 2005 Annual Meeting of
Stockholders, which was filed with the SEC on April 27, 2005. This
document is available free of charge at the SEC's web site at
http://www.sec.gov/ and from Investor Relations at Corgentech as
described above. DATASOURCE: Corgentech Inc. CONTACT: Jennifer Cook
Williams, Senior Director, Investor Relations of Corgentech Inc.,
+1-650-624-9600, or Web site: http://www.algorx.com/ Web site:
http://www.corgentech.com/
Copyright
Corgentech (NASDAQ:CGTK)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Corgentech (NASDAQ:CGTK)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024